ライフサイエンスコーパス: yellow fever

1 ector for arboviruses (e.g. dengue, zika and yellow fever).

2 tion during investigations on the ecology of yellow fever.

3 tuberculosis to 8043 (95% CI 7621-8464) for yellow fever.

4 mopolitan vector of dengue, chikungunya, and yellow fever.

5 there is no specific antiviral treatment for yellow fever.

6 its derivatives as antiviral agents to treat yellow fever.

7 iral therapeutics for clinical management of yellow fever.

8 and 38% were visiting countries endemic for yellow fever.

9 ncluding smallpox, polio, measles, mumps and yellow fever.

10 ored diseases such as bovine tuberculosis or yellow fever.

11 of a vaccine to protect the species against yellow fever.

12 first death of a golden lion tamarin due to yellow fever.

13 ctors that may favor the mosquito vectors of yellow fever.

14 cases (rubella, -4.5% [95% CI -9.5 to -0.1]; yellow fever, 1.2% [-2.9 to 5.5]).

15 rus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express

16 than candidates based on Langat E5, TBE, and yellow fever 17D backbones, and was found to be highly i

17 and envelope (E) sequences inserted into the yellow fever 17D vaccine genome.

18 Yellow fever 17D vaccine is one of the most successful v

19 us serotypes 1 to 4 (DENV1 to DENV4) and the yellow fever 17D vaccine strain (YFV-17D) did not antago

20 ruses, dengue virus serotypes 1 to 4 and the yellow fever 17D vaccine strain, did not antagonize STAT

21 irus (LGTV), a former live TBEV vaccine; and yellow fever 17D virus vaccine (YF 17D) in rhesus monkey

22 Live chimeric yellow fever 17D/TBE, Dengue 2/TBE, and Langat E5/TBE ca

23 ibodies elicited by the tetravalent chimeric yellow fever-17D/dengue vaccine or DENV infection.

24 aegypti mosquito, that also carries dengue, yellow fever and chikungunya viruses.

25 In the yellow fever and dengue vector Aedes aegypti, both sexes

26 , and asymptomatic infection predominates in yellow fever and dengue viral infections.

27 edes aegypti is the principal vector for the yellow fever and dengue viruses, and is also responsible

28 k-borne encephalitis, Japanese encephalitis, yellow fever and dengue viruses, constitute a significan

29 gens responsible for other diseases, such as yellow fever and dengue.

30 borne infectious diseases such as dengue and yellow fever and emerging diseases such as Zika and chik

31 o emergency situations, such as outbreaks of yellow fever and meningococcal meningitis.

32 om at-risk countries were vaccinated against yellow fever and polio.

33 th particular examples from studies with the yellow fever and the seasonal influenza vaccines.

34 mitigate the spread of chikungunya, dengue, yellow fever and Zika viruses must consider the so far u

35 ito-transmitted flaviviruses include dengue, yellow fever and Zika viruses.

36 and is the main worldwide vector of dengue, yellow fever, and chikungunya viruses.

37 e flaviviruses responsible for dengue fever, yellow fever, and chikungunya.

38 for other flaviviruses, including West Nile, yellow fever, and dengue viruses, and the critical role

39 other Flaviviridae, including dengue, Zika, yellow fever, and West Nile virus, identifies conserved

40 Zika virus is a flavivirus like the dengue, yellow fever, and West Nile viruses.

41 viral diseases (notably dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the

42 mosquitoes can transmit dengue, chikungunya, yellow fever, and Zika viruses.

43 tion serum samples for measles, rubella, and yellow fever; and the post-vaccination antibody titres g

44 g the participants who were seronegative for yellow fever antibody at baseline varied significantly a

45 The rubella and yellow fever antibody titres were reduced by co-administ

46 97%; 95% CI, 96 to 98) were seropositive for yellow fever antibody.

47 the XRX-001 vaccine, containing inactivated yellow fever antigen with an alum adjuvant, induced neut

48 est Nile fever, tick-borne encephalitis, and yellow fever, are endemic in tropical and temperate part

49 ion were included; children seropositive for yellow fever at baseline were excluded.

50 oduce Bayesian model averaged predictions of yellow fever burden across the African endemic region.

51 The yellow fever burden in Africa was estimated for the year

52 ramework for model comparison and predicting yellow fever burden in Africa.

53 ffective vaccine is available, the number of yellow fever cases has increased over the past two decad

54 om mosquito-borne diseases-including dengue, yellow fever, chikungunya and Zika-is expanding in conce

55 Dengue, yellow fever, chikungunya, and Zika viruses have undergo

56 Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/J

57 ka virus, and the threat of global spread of yellow fever, combined with the resurgence of dengue and

58 vaccination coverage for polio, measles, and yellow fever continued to decrease, whereas the trend in

59 elping to allocate resources efficiently for yellow fever control.

60 7, is a mosquito-borne flavivirus related to yellow fever, dengue and West Nile viruses.

61 vectors for malaria and the latter for Zika, yellow fever, dengue, and chikungunya.

62 tempt to control the mosquito-borne diseases yellow fever, dengue, chikungunya, and Zika fevers, a st

63 It is closely related to yellow fever, dengue, Japanese encephalitis, and West Ni

64 It is closely related to the mosquito-borne yellow fever, dengue, Japanese encephalitis, and West Ni

65 ito-borne or tick-borne flaviviruses such as yellow fever, dengue, West Nile, St Louis encephalitis,

66 egypti mosquitoes transmit pathogens such as yellow fever, dengue, Zika, and chikungunya viruses to m

67 CE Arbovirus infections in Brazil, including yellow fever, dengue, zika, and chikungunya, result in c

68 14c10 light chain CDRs.IMPORTANCE A chimeric yellow fever-dengue live-attenuated tetravalent vaccine

69 Sanofi Pasteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue

70 igned to explore the effects of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD-TDV

71 Contemporary estimates of the yellow fever disease burden are lacking, and the present

72 The ongoing yellow fever epidemic in Angola strains the global vacci

73 theastern Brazil experienced the most severe yellow fever epidemic/epizootic in the country in 80 yea

74 egypti is the principal vector of dengue and yellow fever flaviviruses.

75 in the level of all vaccinations except for yellow fever for which the reduction was marginal.

76 Since late 2015, an epidemic of yellow fever has caused more than 7334 suspected cases i

77 Yellow fever has never previously been reported in trans

78 after a period of low vaccination coverage, yellow fever has resurged in the continent.

79 c diseases, such as cholera, meningitis, and yellow fever, have become common over the past decade, h

80 clones in response to primary and secondary yellow fever immunization - the model for acute infectio

81 ferent subsets of cCXCR5(+) T cell following yellow fever immunization.

82 The first reported case of yellow fever in a kidney transplant recipient in Brazil

83 Substantial outbreaks of yellow fever in Angola and Brazil in the past 2 years, c

84 timate the effective reproductive number for yellow fever in Angola using disease natural history and

85 say to measure protective antibodies against yellow fever in Malian and Ghanaian children vaccinated

86 late 2016 Brazil faced the worst outbreak of Yellow Fever in recent decades, mainly located in southe

87 in Africa during the 1940s to 1960s reduced yellow fever incidence for several decades.

88 nd of the Americans during the Cold War with yellow fever-infected mosquitoes.

89 Yellow fever is a lethal viral hemorrhagic fever occurri

90 Yellow fever is a vector-borne disease affecting humans

91 Yellow fever is a vector-borne disease endemic in tropic

92 Yellow fever is an acute viral hemorrhagic disease which

93 s a significant health burden in areas where yellow fever is endemic, but it is preventable through v

94 travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serio

95 A single dose of vaccine against yellow fever is routinely administered to infants aged 9

96 des aegypti, the global vector of dengue and yellow fever, is inexorably linked to water-filled human

97 Vaccines are available for yellow fever, Japanese encephalitis and tick-borne encep

98 West Nile fever (WNF), chikungunya, dengue, yellow fever, Japanese encephalitis virus, GBS, and cont

99 VPDs), including polio, measles and rubella, yellow fever, Japanese encephalitis, rotavirus, and inva

100 s including dengue fever, chikungunya, zika, yellow fever, leishmaniasis, chagas disease, and malaria

101 fection (hepatitis C virus) and vaccination (yellow fever, malaria, influenza), but poor outcome in a

102 B virus, and Haemophilus influenzae type b), yellow fever, measles, and tuberculosis.

103 by plaque reduction neutralisation (measles, yellow fever), microneutralisation (polio serotypes 1 an

104 The yellow fever mosquito Aedes aegypti forms aerial swarms

105 fficking, we disrupted COPI functions in the Yellow Fever mosquito Aedes aegypti to interfere with bl

106 The yellow fever mosquito Aedes aegypti, an important vector

107 the effect of geosmin on the behavior of the yellow fever mosquito Aedes aegypti.

108 malaria mosquito Anopheles stephensi and the yellow fever mosquito Aedes aegypti.

109 s in the genome of a divergent relative, the yellow fever mosquito Aedes aegypti.

110 To reproduce, the female yellow fever mosquito has to find a human host.

111 gand selectivity and in vivo function of the yellow fever mosquito sterol carrier protein-2 protein (

112 apidly displaced resident populations of the yellow fever mosquito, Aedes aegypti in the southeastern

113 rticles in midgut, fat body and epidermis of yellow fever mosquito, Aedes aegypti larvae.

114 locus) establishes the male sex (M/m) in the yellow fever mosquito, Aedes aegypti Nix, a gene in the

115 ed neuropeptides in the antennal lobe of the yellow fever mosquito, Aedes aegypti, a major vector of

116 Prior studies with the yellow fever mosquito, Aedes aegypti, indicated blood fe

117 The yellow fever mosquito, Aedes aegypti, particularly in Ne

118 colactone may be an interkingdom cue for the yellow fever mosquito, Aedes aegypti, seeking blood-meal

119 The yellow fever mosquito, Aedes aegypti, the global vector

120 By using the yellow fever mosquito, Aedes aegypti, we demonstrate tha

121 se mosquito, Culex quinquefasciatus, and the yellow fever mosquito, Aedes aegypti.

122 co-mediated activation of spermatozoa in the yellow fever mosquito, Aedes aegypti.

123 ystem in the fat body of fruit flies and the yellow fever mosquito, Aedes aegypti.

124 no-acid transporter Slimfast (Slif) from the yellow-fever mosquito Aedes aegypti using codon-optimize

125 ET-elicited protection against ZIKV-infected yellow fever mosquitoes from old and recent laboratory c

126 evious estimates on the basis of more recent yellow fever occurrence data and improved estimation met

127 are coupled to a generalised linear model of yellow fever occurrence which uses environmental covaria

128 ion kinetics, innate gene activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccine

129 graphic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas

130 graphic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas

131 In 2016, the response to a yellow fever outbreak in Angola and the Democratic Repub

132 Yellow fever outbreaks have continued to occur and cause

133 were fitted to a dataset of the locations of yellow fever outbreaks within the last 25 years to estim

134 ulation immunity threshold for prevention of yellow fever outbreaks.

135 doses and the lack of therapeutic agents for yellow fever put global health at risk, should this viru

136 complete follow-up history, and no record of yellow fever revaccination were included; children serop

137 between 43% and 52% of the population within yellow fever risk zones, compared with between 66% and 7

138 still exist in contemporary coverage within yellow fever risk zones.

139 rus seroprevalence and measles, rubella, and yellow fever seroconversion, and (1/3) log2 for log2-tra

140 t human pathogens such as dengue, West Nile, yellow fever, tick-borne encephalitis and Japanese encep

141 tavirus, measles, meningitis A, rubella, and yellow fever to approximate the future deaths averted be

142 r models assume contrasting scenarios of the yellow fever transmission cycle in Africa.

143 model which suggests a higher proportion of yellow fever transmission occurs as a result of infectio

144 We examine two established models of yellow fever transmission within a Bayesian model averag

145 With simple mathematical models of yellow fever transmission, we calculate the infection at

146 h-service-provider registeries) reporting on yellow fever vaccination activities between May 1, 1939,

147 e aims of this study were to estimate global yellow fever vaccination coverage from 1970 through to 2

148 ION: Our results highlight important gaps in yellow fever vaccination coverage, can contribute to imp

149 t) of 18 US clinics registered to administer yellow fever vaccination.

150 of antibody responses to both influenza and yellow fever vaccinations in healthy subjects.

151 As a result, a fractional dose of the 17DD yellow fever vaccine (containing one fifth [0.1 ml] of t

152 The live yellow fever vaccine (YF-17D) offers a unique opportunit

153 iremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril).

154 Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal

155 The yellow fever vaccine (YFV) has been broadly used as a mo

156 dividuals immunized with the live attenuated yellow fever vaccine (YFV-17D) by sampling peripheral bl

157 t transcriptomic gene expression profiles in Yellow Fever vaccine 17D (YF-17D) immunized human subjec

158 oenvironment to the response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort.

159 The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most eff

160 viral Ab responses, following infection with yellow fever vaccine 17D strain.

161 ology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope ge

162 Vaccination with the yellow fever vaccine causes a systemic acute viral infec

163 on of the population who had ever received a yellow fever vaccine for each second level administrativ

164 Although a highly effective yellow fever vaccine has been available for more than se

165 Yellow fever vaccine has proven effective, but vaccinati

166 ly dynamic in humans after subcutaneous live yellow fever vaccine immunization.

167 whole-virus, beta-propiolactone-inactivated yellow fever vaccine produced in Vero cell cultures and

168 2)-expressing plasmid (EP rDNA plus pIL-12), yellow fever vaccine virus 17D (rYF17D), and recombinant

169 The live-attenuated yellow fever vaccine virus 17D (YF17D) has many properti

170 We show that recombinant attenuated yellow fever vaccine virus 17D expressing simian immunod

171 eta production in response to CpG DNA or the yellow fever vaccine virus strain 17D.

172 A fractional dose of the 17DD yellow fever vaccine was effective at inducing seroconve

173 Symptoms associated with yellow fever vaccine were less frequent in the TY014 gro

174 The yellow fever vaccine YF-17D is one of the most successfu

175 For example, the yellow fever vaccine YF-17D, one of the most successful

176 d immune responses in humans vaccinated with yellow fever vaccine YF-17D.

177 o adjuvanted vaccines or the live-attenuated yellow fever vaccine.

178 , robust response to MRKAd5/HIV with that to yellow fever vaccine.

179 nteers immunized with the highly efficacious yellow fever vaccine.

180 epublic of Congo led to a global shortage of yellow fever vaccine.

181 IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when given as a fu

182 serum in the 1918 flu epidemic, contaminated yellow fever vaccines in World War II, and unethical hum

183 -administration of IPV, measles-rubella, and yellow fever vaccines within the Expanded Programme on I

184 ned to receive the IPV, measles-rubella, and yellow fever vaccines, singularly or in combination.

185 ved with antibody responses to influenza and yellow fever vaccines.

186 ent oral poliovirus (OPV), rubella, measles, yellow fever, varicella-zoster, multivalent measles/mump

187 ry gland anticoagulant from the mosquito and yellow fever vector Aedes albopictus, has been character

188 ified Wolbachia in Kenyan populations of the yellow fever vector Aedes bromeliae and its relative Aed

189 analysed datasets describing the epidemic of yellow fever, vector suitability, human demography, and

190 milar to that induced by the live attenuated yellow fever viral vaccine.

191 e a high mosquito infectivity phenotype, the yellow fever virus (YFV) 17D backbone of the ChimeriVax-

192 The live attenuated yellow fever virus (YFV) 17D vaccine provides a good mod

193 phosphorylation sites of the NS5 proteins of yellow fever virus (YFV) and dengue virus (DENV), two fl

194 tricts two medically important flaviviruses, yellow fever virus (YFV) and dengue virus serotype 2 (DE

195 Arboviruses such as yellow fever virus (YFV) are transmitted between arthrop

196 out metagenomic sequencing which implicated yellow fever virus (YFV) as the etiology of this outbrea

197 In the present study we characterize the Yellow Fever Virus (YFV) associated with this outbreak i

198 Yellow fever virus (YFV) can induce acute, life-threaten

199 The recent yellow fever virus (YFV) epidemic in Brazil in 2017 and

200 etime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading

201 The recent reemergence of yellow fever virus (YFV) in Brazil has raised serious co

202 e previously demonstrated to be required for yellow fever virus (YFV) infection and others subsequent

203 Hepatocytes are a major target of yellow fever virus (YFV) infection, and the coagulopathy

204 Here we show that yellow fever virus (YFV) inhibits IFN-I signaling throug

205 sequencing is presented using as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and

206 It was previously reported that mutations in yellow fever virus (YFV) nonstructural protein NS2A bloc

207 gue virus (DENV), West Nile virus (WNV), and yellow fever virus (YFV) NS1 attenuate classical and lec

208 verexpressed DNAJC14 is targeted to sites of yellow fever virus (YFV) replication complex (RC) format

209 A molecular clone of yellow fever virus (YFV) strain 17D was used to identify

210 safety and immunogenicity of live attenuated yellow fever virus (YFV) vaccination of nonatopic subjec

211 In this study, we used the live attenuated yellow fever virus (YFV) vaccine 17D as a human in vivo

212 Here we address this issue using the live yellow fever virus (YFV) vaccine, which induces long-ter

213 th threats, including dengue viruses (DENV), yellow fever virus (YFV), and Zika virus (ZIKV).

214 of many important human pathogens including yellow fever virus (YFV), dengue virus (DENV), and Zika

215 that TRIM56 poses a barrier to infections by yellow fever virus (YFV), dengue virus serotype 2 (DENV2

216 low Fever (YF) is a severe disease caused by Yellow Fever Virus (YFV), endemic in some parts of Afric

217 importance, such as dengue virus (DENV) and yellow fever virus (YFV), originated in sylvatic transmi

218 Using yellow fever virus (YFV), we demonstrate that DNAJC14 re

219 + T cells specific for a single epitope from Yellow Fever Virus (YFV), we show that the recently desc

220 flaviviruses.IMPORTANCE Flaviviruses such as yellow fever virus (YFV), Zika virus (ZIKV), and dengue

221 Mosquito-borne flaviviruses, including yellow fever virus (YFV), Zika virus (ZIKV), and West Ni

222 ine (BDAA) compound, which potently inhibits yellow fever virus (YFV).

223 izing antibodies for dengue virus (DENV) and yellow fever virus (YFV).

224 e insights into how a prototypic flavivirus, yellow fever virus (YFV-17D), differentially interacts w

225 ed mice before and after vaccination against yellow fever virus (YFV-17D).

226 DV, hepatitis C virus, West Nile virus, and yellow fever virus (YFV; vaccine strain 17D) were expres

227 he related mosquito-transmitted flaviviruses yellow fever virus 17D (YFV) and dengue virus type 2 (DE

228 nally track the human B cell response to the yellow fever virus 17D (YFV-17D) vaccine.

229 wing ex vivo exposure to the live attenuated yellow fever virus 17D strain vaccine, a virus that we s

230 s of the flavivirus dengue virus (DV) and by yellow fever virus 17D were cholesterol independent, and

231 ext of published studies of vaccines against yellow fever virus and influenza virus.

232 sis of CD8(+) T cells responding to the live yellow fever virus and smallpox vaccines--two highly suc

233 include the 2 flaviviruses dengue virus and yellow fever virus and the alphavirus chikungunya virus,

234 revaccination or natural infection with wild yellow fever virus during a 2011-12 outbreak in northern

235 rm persistence of neutralising antibodies to yellow fever virus following routine vaccination in infa

236 s such as Zika virus, chikungunya virus, and yellow fever virus have drawn attention toward other coc

237 ssessed neutralizing antibody titers against yellow fever virus in blood samples obtained before vacc

238 ave caused large outbreaks, such as Zika and Yellow Fever Virus in Brazil.

239 eplication of infectious West Nile virus and yellow fever virus in cell culture with low toxicity.

240 ogistic model to infer the district-specific yellow fever virus infection risk during the course of t

241 cokinetics of TY014, a fully human IgG1 anti-yellow fever virus monoclonal antibody.

242 Dengue, West Nile, or yellow fever virus NS1 directly associated with C4b bind

243 directed against a conserved immunodominant yellow fever virus NS3 epitope.

244 timated timing, source, and likely routes of yellow fever virus transmission and dispersion during on

245 trative division across countries at risk of yellow fever virus transmission from 1970 to 2016.

246 till require vaccination in areas at risk of yellow fever virus transmission to achieve the 80% popul

247 This live attenuated yellow fever virus vaccine yields sterile, long-term imm

248 The early spread of yellow fever virus was characterised by fast exponential

249 ax-II), rotavirus (Rotateq and Rotarix), and yellow fever virus were negative for XMRV and highly rel

250 ift Valley fever virus, West Nile virus, and yellow fever virus), 8 bacteria (Bartonella spp., Brucel

251 us, Murray Valley virus, Powassan virus, and yellow fever virus).

252 Arboviruses like dengue virus, yellow fever virus, and West Nile virus are enveloped pa

253 ae family, including dengue virus (DENV) and yellow fever virus, cause serious disease in humans, whi

254 ing three members of the family Flaviviridae(yellow fever virus, dengue virus, and bovine viral diarr

255 Flaviviruses, such as Zika virus, yellow fever virus, dengue virus, and West Nile virus (W

256 ephalitis virus, norovirus, metapneumovirus, yellow fever virus, Japanese encephalitis virus, parainf

257 d mosquito-borne flaviviruses, which include yellow fever virus, Sepik virus, Saboya virus, and other

258 wide range of viruses, including DENV, WNV, yellow fever virus, Sindbis virus, Venezuelan equine enc

259 animal viruses, including hepatitis C virus, yellow fever virus, West Nile virus, chikungunya virus,

260 sed analyses of mass cytometry data, we show yellow fever virus-specific cCXCR5 T cells elicited by v

261 , such as dengue virus, West Nile virus, and yellow fever virus.

262 rica to understand and predict the spread of yellow fever virus.

263 es or West Nile virus, or vaccinated against yellow fever virus.

264 iated mosquito-borne flaviviruses, including yellow fever virus.

265 munodeficiency virus, influenza A virus, and yellow fever virus.

266 nfection and cell death by DENV-2, ZIKV, and yellow fever virus.

267 s, including pathogens such as influenza and yellow fever virus.

268 nd-concomitantly-protective immunity against yellow fever virus.

269 dengue virus (DENV), Zika virus (ZIKV), and yellow fever virus.

270 However, dengue, chikungunya, and yellow fever viruses have repeatedly initiated urban tra

271 tion of Zika, Ebola, dengue, chikungunya and yellow fever viruses in plasma samples from infected pat

272 The past evolution of the dengue and yellow fever viruses provides clues about the influence

273 vectors of African malaria, dengue fever and yellow fever viruses, and lymphatic filariasis, respecti

274 aviviruses, including West Nile, dengue, and yellow fever viruses, is capable of inducing variable de

275 o many flavivirus types including Dengue and yellow fever viruses, the nonstructural NS3 multifunctio

276 ot neutralize or immune-precipitate mumps or yellow fever viruses.

277 diseases that include West Nile, dengue and yellow fever viruses.

278 ain vector of dengue, Zika, chikungunya, and yellow fever viruses.

279 r medically-important flaviviruses including yellow fever, West Nile and Japanese encephalitis viruse

280 aks, including those caused by dengue, Zika, yellow fever, West Nile, and chikungunya viruses, to dem

281 transmits two major arboviruses, dengue and yellow fever, which cause significant global morbidity a

282 ntibody concentrations with reference to the yellow fever WHO International Standard.

283 g the most prevalent transmission routes for yellow fever will be limited by the sparsity of data whi

284 d Japanese encephalitis vaccination enhanced yellow fever (YF) immunogenicity upon YF vaccination.

285 Yellow fever (YF) is a mosquito-transmitted viral diseas

286 Yellow Fever (YF) is a severe disease caused by Yellow F

287 Yellow fever (YF) is a vector-borne viral hemorrhagic di

288 Yellow Fever (YF) is an arbovirus endemic in tropical re

289 Yellow fever (YF) is still a major public health problem

290 ing in 2016, Brazil faced one of the largest Yellow Fever (YF) outbreaks in recent decades, mainly in

291 Southeast Brazil has experienced two large yellow fever (YF) outbreaks since 2016.

292 The attenuated yellow fever (YF) vaccine (YF-17D) was developed in the

293 induced by immunization with live-attenuated yellow fever (YF) vaccine.

294 e cap-binding pocket of the dengue (DEN) and yellow fever (YF) virus MTase enzymes.

295 gainst measles, mumps, and rubella (MMR) and yellow fever (YF) with live attenuated viruses can rarel

296 y-transplanted patient, unvaccinated against yellow fever (YF), developed high fever, progressed rapi

297 Providers must counsel travelers to yellow fever (YF)-endemic areas, although risk estimates

298 s repeated outbreaks of Chikungunya (CHIKV), Yellow fever (YFV) and Japanese encephalitis (JEV) virus

299 ese encephalitis (JEV), West Nile (WNV), and yellow fever (YFV) viruses by intracellular cytokine sta

300 regions, is the principal vector of dengue, yellow fever, Zika and Chikungunya viruses.